Mads Krogsgaard Thomsen, CEO of Novo Nordisk Foundation, discusses European competitiveness.

European equities rose on Tuesday on relief that US President Donald Trump had refrained from immediately targeting the region with trade tariffs.

The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027 ...

Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...

Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...

Trump added Denmark to his growing list of tariff targets — including Canada, Mexico and China — as he has increasingly ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

That figure is likely even higher for 2024 because Novo Nordisk, the Danish pharmaceutical giant, makes one of the hottest drugs on the market: Ozempic. Americans have increasingly turned to ...

The collaboration now encompasses additional drug programmes. Credit: aslysun/Shutterstock. Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, ...

Novo Nordisk is increasing its U.S. production to ... the company serves much of the U.S. market from a factory in Mexico, as well as a new carbon-neutral facility in Virginia.

If successful in later stage trials, the company will be entering into a market space currently dominated by Novo Nordisk’s Weygovy and Eli Lilly’s Zepbound with the new entrant having the significant ...